🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Such a courageous and inspiring story of a leading thoracic oncologist and her journey with breast cancer and not skipping a beat with her commitment to her patients and research. Even Better if you understand Hindi but still worth a watch! Proud to know you Vanita Noronha, MBBS MD DM

Celebrating each one of you. You are kind, you are tender , you are a leader, you are a force to reckon with. Thank you to all the incredible women who support Lung Connect India selflessly . We are grateful to you. #lungcancer #WomensDay #womenpower #celebratingwomen

Early diagnosis can save lives says Dr Ankita Chitre: Womens Day Special (ankita chitre) #lungconnectindiafoundation #lungconnect #CancerWarriorsUnite #healthcare #cancertreatment #cancersupportcommunity #cancercare #AwarenessMatters #lungcancer #women #womensupportingwomen

Why do some lung cancer patients relapse early on targeted therapy? Our study with Drs. K Prabhash, Vanita Noronha, MBBS MD DM & team from Tata Memorial Hospital in collab with Drs. J Khandare, G Shafi, & team from OneCell Diagnostics published in ESMO Open (ESMO Open) sheds insights. sciencedirect.com/science/articl…

#Financialtoxicity kills ppl more than #cancer does A 'poor' pt diag with stage 4 alk+ NSCLC , has been on #tki for the last 2.5 yrs. He has been financially supported by NGO's, diff govt schemes. Now all resources r exhausted. Jagat Prakash Nadda PMO India Narendra Modi Ministry of Health +

Cuz the financial toxicity is worse than the death Of their loved one! This is 💔 . I request the government of India to plz include tki's in the #AyushmanBharat yojna. Every citizen of this nation deserves a fair chance at treatment irrespective of their financial status.

Publication alert 🚨 Bone invasion, perineural invasion, >/=5 positive lymph nodes and lymph node ratio >/=0.1 predict extra-nodal extension in oral cancers. Cancer Research, Statistics and Treatment Vanita Noronha, MBBS MD DM Tata Memorial Hospital FHNO NationalCancerGrid Cancer Awareness Conquer Cancer, the ASCO Foundation #Oncology

Our new issue is live! Looking forward to your comments and criticism. Sincere thanks to all authors, reviewers, editors, and publishers for your contribution. Read here: bit.ly/3Kf29px Vanita Noronha, MBBS MD DM Tata Memorial Hospital #CRST #Oncology #CancerResearch #MedTwitter

Thanks ASCO for the opportunity to serve as track chair for Developmental Therapeutics/Immunotherapy! Check out our Clinical Science Symposium #ASCO25 'Real-World Immunotherapy' 📅2 June 16h30-18h00 💡Ph III De-escalation Trial, Time-of-day & IO, IO+transplant OncoAlert #LCSM

link.springer.com/article/10.100… “Prevalence and impact of financial toxicity in older patients with cancer: a prospective observational study in India” published in Supportive Care in Cancer- Springer Nature #Research #cancercare #financial #financialtoxicity #chemotherapy #compassion

Mutational landscape on Indian patients with Lung #cancer #lcsm Beautiful article Journal of Clinical Oncology from Vanita Noronha, MBBS MD DM, Dr Kumar Prabhash Minit Shah Nandini Menon Longing for a day where p53 becomes a targetable mutation! CORE Diagnostics Dr Amol Akhade Goutham Sunny Praveen Kumar Marimuthu

1/n..Under the aegis of CRSF - Cancer Research and Statistic Foundation and guidance of Dr (Prof). Vijay Patil, Vanita Noronha, MBBS MD DM, Dr. Kumar sir, our long-awaited study on Triple Metronomic therapy was published in The Cancer Letter. Please read and comment. kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…

Lung Connect India Foundation invites you to join our 37th Geriatric OPD Support Group Meeting Sanjeev Sharma Vanita Noronha, MBBS MD DM #lunghealth #cancersupportcommunity #patientengagement #lungcancer #lungcancerawareness #geriatrics

Today is #WorldClinicalTrialDay- 2025. Clinical Trials are very important is shaping the future treatment of lung cancer patients. 🎗Access to New Treatments: Clinical trials provide patients with early access to new therapies that are not yet widely available. 🎗Cutting-Edge

🚨Looking forward to these #novel studies at #ASCO25 ASCO #DevpTherapeutics ◼️ Fascin inhibition for ICI-refractory cancers ◼️ B7-H4 & integrin β6 ADCs ◼️ Ultra-low-dose IO in India (DELII) ◼️ Time-of-day impact on IO-chemo ◼️ KRAS G12D, MTAP, KIF18A inhibitors OncoAlert 👇

🚨 Just published in JCO Global Oncology 📢 Our phase III METRO-CHASE trial shows triple oral metronomic chemotherapy significantly improves survival in platinum-refractory. #HeadAndNeckCancer. 🔗 doi.org/10.1200/GO-25-… #oncology #cancerresearch

dailynews.ascopubs.org/do/all-oral-tr… Our Randomised trial of Triple OMCT got place in ASCO News!!! Thanks to my mentors: Prof. Prabhash, Prof Vanita Noronha, MBBS MD DM, Prof. Banavali ASCO ESMO - Eur. Oncology #GlobalOncology Bishal Gyawali, MD, PhD, FASCO Vanita Noronha, MBBS MD DM Dr (Prof). Vijay Patil Dr Amol Akhade

NEWS FROM INDUSTRY: Source MERCK Update HERTHENA-Lung02 🫁 Daiichi Sankyo and Merck have voluntarily withdrawn their Biologics License Application seeking accelerated approval for patritumab deruxtecan (HER3-DXd) in the U.S. 🇺🇸for EGFR-mutated 🧬advanced non-small cell

Our new issue is live! Looking forward to your comments and criticism. Sincere thanks to all authors, reviewers, editors, and publishers for their contribution. Read here: bit.ly/3Kf29px Vanita Noronha, MBBS MD DM Tata Memorial Hospital #CRST #Oncology #CancerResearch #MedTwitter

#ASCO25 💡Highlight of the Developmental Therapeutics/IO track today Real World Immunotherapy, Hall D2 - Ph III Ultra low-dose Nivo 🇮🇳 Vanita Noronha, MBBS MD DM - Time-of-day IO 🇫🇷 #FrancisLevi - IO in transplant 🇯🇴 #MuntaserZayoud - Discussants 🇫🇷 Jordi Remon 🇺🇸 Elad Sharon